386 related articles for article (PubMed ID: 25157544)
1. Papillary thyroid cancer: factors involved in restaging N1 disease after total thyroidectomy and radioactive iodine treatment.
Guy A; Hirsch D; Shohat T; Bachar G; Tirosh A; Robenshtok E; Shimon I; Benbassat CA
J Clin Endocrinol Metab; 2014 Nov; 99(11):4167-73. PubMed ID: 25157544
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
[TBL] [Abstract][Full Text] [Related]
3. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.
Leboulleux S; Rubino C; Baudin E; Caillou B; Hartl DM; Bidart JM; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2005 Oct; 90(10):5723-9. PubMed ID: 16030160
[TBL] [Abstract][Full Text] [Related]
5. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
Grigsby PW; Reddy RM; Moley JF; Hall BL
Surgery; 2006 Dec; 140(6):1043-7; discussion 1047-9. PubMed ID: 17188155
[TBL] [Abstract][Full Text] [Related]
6. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
7. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases.
Sabra MM; Grewal RK; Ghossein RA; Tuttle RM
Thyroid; 2014 Jul; 24(7):1088-95. PubMed ID: 24559250
[TBL] [Abstract][Full Text] [Related]
8. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
9. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
10. Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer.
Sun Y; Sun Q; Tian J; He X
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1413-e1423. PubMed ID: 37167097
[TBL] [Abstract][Full Text] [Related]
11. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition.
Chow SM; Yau S; Kwan CK; Poon PC; Law SC
Endocr Relat Cancer; 2006 Dec; 13(4):1159-72. PubMed ID: 17158761
[TBL] [Abstract][Full Text] [Related]
12. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up.
Pedrazzini L; Baroli A; Marzoli L; Guglielmi R; Papini E
Minerva Endocrinol; 2013 Sep; 38(3):269-79. PubMed ID: 24126547
[TBL] [Abstract][Full Text] [Related]
13. Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma.
Gorshtein A; Benbassat C; Robenshtok E; Shimon I; Hirsch D
World J Surg; 2016 Sep; 40(9):2123-30. PubMed ID: 27094559
[TBL] [Abstract][Full Text] [Related]
14. Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy.
Burningham AR; Krishnan J; Davidson BJ; Ringel MD; Burman KD
Otolaryngol Head Neck Surg; 2005 Jun; 132(6):840-4. PubMed ID: 15944551
[TBL] [Abstract][Full Text] [Related]
15. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
16. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients.
Kim KJ; Kim SM; Lee YS; Chung WY; Chang HS; Park CS
Ann Surg Oncol; 2015 Jan; 22(1):125-31. PubMed ID: 25092159
[TBL] [Abstract][Full Text] [Related]
18. Influence of previous radiation exposure on pathologic features and clinical outcome in patients with thyroid cancer.
Seaberg RM; Eski S; Freeman JL
Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):355-9. PubMed ID: 19380356
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas.
Lin JD; Chao TC; Hsueh C
Clin Endocrinol (Oxf); 2007 Feb; 66(2):224-8. PubMed ID: 17223992
[TBL] [Abstract][Full Text] [Related]
20. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
